NASDAQ · SXTP
Healthcare · Biotechnology
$1.44
Down-$0.33 (-22.92%)
Updated Oct 6, 2026, 11:06 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SXTP
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
SXTP closed at $1.44 after 20 trading sessions, up 47.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.55 | $1.66 | $1.361 | $1.44 | 630.08K |
| Oct 2, 2026 | $1.28 | $1.4499 | $1.22 | $1.39 | 199.92K |
| Oct 1, 2026 | $1.29 | $1.39 | $1.23 | $1.25 | 137.22K |
| Sep 30, 2026 | $1.23 | $1.34 | $1.18 | $1.33 | 111.79K |
| Sep 29, 2026 | $1.27 | $1.30 | $1.21 | $1.25 | 146.87K |
| Sep 28, 2026 | $1.17 | $1.25 | $1.14 | $1.25 | 80.26K |
| Sep 25, 2026 | $1.16 | $1.17 | $1.12 | $1.17 | 35.06K |
| Sep 24, 2026 | $1.16 | $1.20 | $1.09 | $1.15 | 52.9K |
| Sep 23, 2026 | $1.04 | $1.16 | $1.04 | $1.16 | 54.15K |
| Sep 22, 2026 | $0.96 | $1.10 | $0.96 | $1.04 | 74.83K |
| Sep 21, 2026 | $0.98 | $1.0199 | $0.94 | $1.01 | 24.19K |
| Sep 18, 2026 | $0.97 | $0.99 | $0.9203 | $0.956 | 31.54K |
| Sep 17, 2026 | $0.96 | $1.04 | $0.85 | $0.9926 | 179.91K |
| Sep 16, 2026 | $0.919 | $0.9669 | $0.86 | $0.924 | 125.75K |
| Sep 15, 2026 | $0.90 | $0.90 | $0.84 | $0.8464 | 61.92K |
| Sep 14, 2026 | $0.91 | $0.9501 | $0.8817 | $0.8985 | 110.58K |
| Sep 11, 2026 | $0.9605 | $0.9605 | $0.90 | $0.90 | 57.96K |
| Sep 10, 2026 | $0.9402 | $1.005 | $0.92 | $0.93 | 129.96K |
| Sep 9, 2026 | $0.98 | $0.9995 | $0.93 | $0.9402 | 30.61K |
| Sep 8, 2026 | $0.92 | $1.04 | $0.9102 | $0.9768 | 84.72K |
The latest Smart Investors Daily articles mentioning SXTP.
Company
Market Activity
Research & News
SXTP research
Company profile and research snapshot.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 22, 2026 | Ascendiant Capital | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 9, 2026 | Ascendiant Capital | Buy | — |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 28, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
ORLANDO, FL / ACCESS Newswire / October 2, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) and Exyn Technologies Inc.
Yahoo · Oct 1, 2026
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier. WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector
Benzinga · Oct 1, 2026
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced
Benzinga · Sep 14, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026099702/ea0305442-8k_60degree.htm
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SXTP.
